Sramana Mitra: How long has this company been around? Matthew Michela: Life Image is 11 years old. Sramana Mitra: You have 11 years’ worth of data that is built up in your system. That data is valuable. My next question is, how do you make that data available to people who are trying to do
Matthew Michela: Because data is so hard to get even in this new world of statistical evaluation in front of us, the data that you use is still inadequate. What data is easily accessible? Claims data or data out of an EHR? That’s real world because I can tell you what I paid for two
Matthew Michela: The second thing we’re doing in this big trend in AI, which I think you’re going to see dramatically more of in 2019 to 2021, is adoption of AI. We spent this first generation of AI creating the new algorithms and the computational tools and outcome. If you look at that entire industry,
Sramana Mitra: My next question is going to be about what trends are you seeing. How are your customers using data? Obviously you have a very rich dataset in your ecosystem. What are some unique and interesting visionary ways that data is being used and interesting applications of it being developed on top of that
An in-depth conversation on the stage of data in the medical world. Sramana Mitra: Let’s start by introducing our audience to yourself as well as Life Image. Matthew Michela: I’m the President and CEO of Life Image. Life Image is a medical evidence-based technology platform that services a wide variety of healthcare entities and partners
Sramana Mitra: What are the open problems in your industry that new entrepreneurs could be starting companies around? Ted Chan: Telehealth is a very big opportunity for making healthcare more seamless, more efficient, and more cost effective. There’s a trend. A lot of consumer health companies have been getting mega-funding. They’re getting a lot of
Sramana Mitra: How would you tackle the issue in any given community? Let’s say you’re a patient in any given community. Given your insurance and its coverage, there aren’t that many options. How do you deal with that in terms of provider choice? Ted Chan: What we’re trying to do is give a patient a
Sramana Mitra: How is it that you have 18 out of the top 25 pharma? Given what you describe, it seems to me like you should be having 25 out of the 25. Tareq Sherif: I agree with you. But it’s a business. Sramana Mitra: What is the explanation though? Tareq Sherif: The explanation is,